The Europe Vascular Graft Market size is estimated to grow at a healthy CAGR during the forecast period.
Factors such as developing efficient and advanced novel products using tissue-engineered and biological materials, increased public awareness of peripheral artery diseases, coronary diseases, and cardiac aneurysms, and the rising prevalence of diabetes are primarily accelerating the European vascular graft market growth. The high frequency of abdominal aneurysms and the rising prevalence of smoking and other risk factors that cause aneurysms, rising prevalence of illnesses, diabetes, End-Stage Renal Disease, hypertension, and vascular occlusions are the primary drivers driving this market's expansion. Over the forecast period, sedentary lifestyles and unhealthy eating habits are also expected to drive product demand. Kidney failure is treated through a kidney transplant, which replaces the missing kidney. Vascular grafts are used in this procedure. During kidney transplantation, vascular grafts are used to repair the renal vessel. As a result, the rising prevalence of end-stage kidney failure is predicted to boost demand for vascular grafts, boosting the market's growth.
The market growth is further expected to drive by the increase in the number of occurrences of vascular disorders, such as hypertension. Over the forecast period, technological advances and an increase in the geriatric population are expected to boost the market. The European vascular graft market is expected to grow due to the rising prevalence of cardiovascular disorders. The rising prevalence of cardiovascular aneurysms resulting from poor eating habits and a sedentary lifestyle continues to be a primary driver of endovascular stent-graft adoption. Because of their comparatively lenient regulatory regulations and the rising prevalence of aneurysms, these markets are projected to grow rapidly in the coming years.
Patients can suffer serious or even fatal consequences as a result of product failures. Several companies' products have been recalled from the market due to product faults or other difficulties over the years. The major challenges to the vascular graft market are the greater cost of research and development and the higher cost of vascular graft procedures. Growth is limited by the high expense of treatment and the problems associated with prosthetic grafts.
This research report on the European vascular graft market has been segmented and sub-segmented based on the following categories:
By Product:
By Raw Material:
By End-User:
By Application:
By Country:
Geographically, the European market is expected to develop significantly during the forecast period due to an increase in the number of biomaterials research projects supported by the European Union in collaboration with medical organizations. Furthermore, the rising prevalence of CVDs in the region and the expanding acceptance of prosthetic graft implantation is likely to drive product demand. Europe is a profitable region because of the expanding number of biomaterials research projects sponsored by the European Union. The vascular graft market in the United Kingdom is the largest in Europe. The need for vascular grafts is being driven by a growing geriatric population across the country. Furthermore, the development of minimally invasive endovascular aneurysm repair will increase the demand for surgery among the elderly. As a result, a variety of healthcare providers will choose from a variety of vascular graft items.
KEY MARKET PLAYERS:
Endologix Inc., LeMaitre Vascular, Inc., MAQUET Holding B.V.B. Braun Melsungen AG, & Co. KG, Medtronic plc, C. R. Bard, Inc., Cardinal Health Inc., Cook Medical Inc., Terumo Corporation, and W. L. Gore & Associates, Inc. are the key players in the European Vascular Graft Market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]